Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia

Schizophrenia Research

Volumn 76, Issue 2-3, 2005, Pages 343-351

  Strassnig, Martin ^a   Brar, Jaspreet Singh ^a   Ganguli, Rohan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antioxidants; Dietary intake; Fatty acids; Nutrition; Schizophrenia

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID; RETINOL; SATURATED FATTY ACID;

ADULT; ARTICLE; COMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY INTAKE; FAT INTAKE; FEMALE; HEALTH SURVEY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NUTRITION; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; STANDARD; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; ANTIOXIDANTS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ENERGY INTAKE; FATTY ACIDS; FEMALE; FOOD HABITS; HUMANS; MALE; RESIDENCE CHARACTERISTICS; SCHIZOPHRENIA;

EID: 20444379627     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.03.002     Document Type: Article

References (80)

1. L. Abedin, E.L. Lien, A.J. Vingrys, and A.J. Sinclair The effects of dietary alpha-linolenic acid compared with docosahexaenoic acid on brain, retina, liver, and heart in the guinea pig Lipids 34 5 1999 475 482
2. L.A. Adler, R. Edson, P. Lavori, E. Peselow, E. Duncan, M. Rosenthal, and J. Rotrosen Long-term treatment effects of vitamin E for tardive dyskinesia Biol. Psychiatry 15;43 12 1998 868 872
3. L.A. Adler, J. Rotrosen, R. Edson, P. Lavori, J. Lohr, R. Hitzemann, D. Raisch, M. Caliguri, and K. Tracy Vitamin E treatment for tardive dyskinesia. Veterans Afairs Cooperative study #394 study group Arch. Gen. Psychiatry 56 9 1999 836 841
4. K. Alaimo, M.A. McDowell, R.R. Briefel, A.M. Bischof, C.R. Caughman, C.M. Loria, and C.L. Johnson Dietary Intake of Vitamins, Minerals, and Fiber of Persons Ages 2 Months and Over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91 Advance Data From Vital and Health Statistics vol. 258 1994 National Center for Health Statistics Hyattsville, Maryland
5. M. Arvindakshan, M. Ghate, P.K. Ranjekar, D.R. Evans, and S.P. Mahadik Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia Schizophr. Res. 62 3 2003 195 204
6. A. Ascherio, and W.C. Willet Health effects of trans fatty acids Am. J. Clin. Nutr. 66 4 Suppl 1997 1006S 1010S
7. J. Assies, R. Lieverse, P. Vreken, R.J. Wanders, P.M. Dingemans, and D.H. Linszen Singnificantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group Biol. Psychiatry 49 6 2001 510 522
8. Y. Barak, M. Swartz, E. Shamir, D. Stein, and A. Weizman Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis Ann. Clin. Psychiatry 10 3 1998 101 105
9. K. Bialostosky Dietary Intake of Mactronutrients, Micronutrients, and Other Dietary Constitutents: United States 1988-1994 Vital Health Stat. vol. 11 (245) 2002 National Center for Health Statistics
10. S. Brown, J. Birthwistle, L. Roe, and C. Thompson The unhealthy lifestyle of people with schizophrenia Psychol. Med. 29 3 1999 697 701
11. G. Champeil-Potokar, I. Denis, B. Goustard-Langelier, J.-M. Allesandri, P. Guesnet, and M. Lavialle Astrocytes in culture require docosahexaenoic acid to restore the n-3/n-6 polyunsaturated fatty acid balance in their membrane phospholipids J. Neurosci. Res. 75 2004 96 106
12. O. Christensen, and E. Christensen Fat consumption and schizophrenia Acta Psychiatr. Scand. 78 1988 587 591
13. M.F. Egan, J. Apud, and R.J. Wyatt Treatment of tardive dyskinesia Schizophr. Bull. 23 1997 583 609
14. A.M. Elkashef, and R.J. Wyatt Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E Schizophr. Bull. 25 4 1999 731 740
15. E.A. Emken, R.O. Adlof, and R.M. Gulley Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and ALAs in young adult males Biochem. Biophys. Acta 1213 1994 277 288
16. R. Emsley, C. Myburgh, P. Oosthuizen, and S.J. van Rensburg Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia Am. J. Psychiatry 159 9 2002 1596 1608
17. R. Emsley, P. Oosthuizen, and S.J. van Rensburg Clinical potential of omega-3 fatty acids in the treatment of schizophrenia CNS Drugs 17 15 2003 1081 1091
18. D.R. Evans, V.V. Parikh, M.M. Khan, C. Coussons, P.F. Buckley, and S.P. Mahadik Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment Prostaglandins, Leukot. Essent. Fat. Acids 69 6 2003 393 399
19. W.S. Fenton, J. Hibbeln, and M. Knable Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia Biol. Psychiatry 47 2000 8 21
20. W.S. Fenton, F. Dickerson, J. Boronow, J.R. Hibbeln, and M. Knable A placebo-controlled trial of omega-3 fatty acid (ethyl-eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia Am. J. Psychiatry 158 2001 2071 2074
21. M.P. Freeman Omega-3-fatty acids in psychiatry: a review Ann. Clin. Psychiatry 12 2000 159 165
22. L.M. Gunne, and P.E. Arden An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia Clin. Neuropharmacol. 16 1 1993 90 95
23. R.T. Holman ω-3 and ω-6 essential fatty acid status in human health and disease S. Yehuda D.I. Mostovsky Handbook of Essential Fatty Acid Biology: Biochemistry, Physiology and Behavioral Neurobiology 1997 Humana Press Totawa, NJ 138 182
24. D.F. Horrobin Schizophrenia as a membrane lipid disorder which is expressed throughout the body Prostaglandins, Leukot. Essent. Fat. Acids 55 1996 3 7
25. D.F. Horrobin The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr. Res. 30 1998 193 208
26. D.F. Horrobin, A.I. Glen, and K. Vaddadi The membrane hypothesis of schizophrenia Schizophr. Res. 13 3 1994 195 207
27. F.B. Hu, R.M. van Dam, and S. Liu Diet and risk of type II diabetes: the role of types of fat and carbohydrate Diabetologia 44 2001 805 817
28. I. Jeding, P.J. Evans, D. Akanmu, D. Dexter, J.D. Spencer, O.I. Aruoma, P. Jenner, and B. Halliwell Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs Biochem. Pharmacol. 49 1995 359 365
29. Joy, C.B., Mumby-Croft, R., Joy, L.A., 2003. Polyunsaturated Fatty Acid Supplementation for Schizophrenia. Cochrane Database Syst Reviews, The Cochrane Collaboration; Issue 2.Oxford: Oxford Update Software, CD001257.
30. L. Kohlmeier Dietary methodology considerations for NHANES III Vital Health Stat., Ser. 4, Doc. Committee Reports 27 1992 81 84
31. P.M. Kris-Etherton, D. Shaffer Taylor, S. Yu-Poth, P. Huth, K. Moriarty, V. Fishell, R.L. Hargrove, G. Zhao, and T.D. Etherton Polyunsaturated fatty acids in the food chain in the United States Am. J. Clin. Nutr. 71 suppl 2000 179S 188S
32. L.H. Kuller Dietary fat and chronic disease: epidemiologic overview J. Am. Diet. Assoc. 97 7 suppl 1997 S9 S15
33. J.S. Kwon, J.T. Snook, G.M. Wardlaw, and D.H. Hwang Effects of diets high in saturated fatty acids, canola oil, or safflower oil on platelet function, thromboxane B2 formation, and fatty acid composition of platelet phospholipids Am. J Clin. Nutr. 54 2 1991 351 358
34. R.D. Lee, D.C. Nieman, and M. Rainwater Comparison of eight microcomputer dietary analysis programs with the USDA Nutrient Data Base for Standard Reference J. Am. Diet. Assoc. 95 1995 858 867
35. J.B. Lohr Oxygen radicals and neuropsychiatric illness. Some speculations Arch. Gen. Psychiatry 48 12 1991 1097 1106
36. J.B. Lohr, R. Kuczenski, and A.B. Niculescu Oxidative mechanisms and tardive dyskinesia CNS Drugs 17 1 2003 47 62
37. S.M. Lopez, S.L. Trimbo, E.A. Mascioli, and G.L. Blackburn Human plasma fatty acid variations and how they are related to dietary intake Am. J. Clin. Nutr. 53 1991 628 637
38. J.P. Madden, S.J. Goodman, and H.A. Guthrie Validity of the 24-hr recall. Analysis of data obtained from elderly subjects J. Am. Dietetic Assoc. 68 2 1976 143 147
39. S.P. Mahadik, and S. Mukherjee Free radical pathology and antioxidant defense in schizophrenia: a review Schizophr. Res. 19 1 1996 1 17
40. S.P. Mahadik, and R.E. Scheffer Oxidative injury and potential use of antioxidants in schizophrenia Prostaglandins, Leukot. Essent. Fat. Acids 55 1-2 1996 45 54
41. S.P. Mahadik, S. Mukherjee, D.F. Horrobin, K. Jenkins, E.E. Correnti, and R.E. Scheffer Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects Psychiatry Res. 93 1996 133 142
42. S. Mahadik, D. Evans, and H. Lal Oxidative stress and role of antioxidant ω-3 essential fatty acid supplementation in schizophrenia Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 463 493
43. M.C. Masters Fatty acids and the peroxisome Mol. Cell. Biochem. 165 1996 83 93
44. R. McCreadie on behalf of the Scottish Schizophrenia Research Group Smoking habits and plasma lipid peroxice and vitamin E levels in never-treated first-episode patients with schizophrenia Br. J. Psychiatry 176 2000 290 293
45. M.A. McDowell, R.R Briefel, K. Alaimo, A.M. Bischof, C.R. Caughman, M.D. Carroll, C.M. Loria, and C.L. Johnson Energy and Macronutrient Intakes of Persons Ages 2 Months and Over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91 Advance Data From Vital and Health Statistics vol. 255 1994 National Center for Health Statistics Hyattsville, Maryland
46. K. Melkersson, and M.L. Dahl Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications Drugs 64 7 2004 701 723
47. J. Mellor, J.D.E. Laugharne, and M. Peet Omega-3 fatty acid supplementation in schizophrenic patients Hum. Psychopharmacol. 11 1996 39 46
48. N. Michael, H. Sourgens, V. Arolt, and A. Erfurth Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C Neuropsychobiology 46 Suppl.1 2002 28 30
49. M. Peet Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results Prostaglandins, Leukot. Essent. Fat. Acids 69 6 2003 477 485
50. M. Peet, J.D.E. Laugharne, N. Rangarajan, D.F. Horrobin, and G. Reynolds Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients J. Psychiatr. Res. 29 1995 227 232
51. M. Peet, J. Brind, C.N. Ramchand, S. Shah, and G.K. Vankar Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia Schizophr. Res. 49 3 2001 243 251
52. J.W. Pettegrew, M.S. Keshevan, K. Panchalingam, S. Strychor, D.B. Kaplan, M.G. Tretta, and M. Allen Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectrosocopy Arch. Gen. Psychiatry 48 1991 563 568
53. M. Phillips, M. Sabas, and J. Greenberg Increased pentane and carbon disulfide in the breath of patients with schizophrenia J. Clin. Pathol. 46 1993 861 864
54. S. Prabakaran, J.E. Swatton, M.M. Ryan, S.J. Huffaker, J.T. Huang, J.L. Griffin, M. Wayland, T. Freeman, F. Dubridge, K.S. Lilley, N.A. Karp, S. Hester, D. Tkachev, M.L. Mimmack, R.H. Yolkern, M.J. Webster, E.F. Torrey, and S. Bahn Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress Mol. Psychiatry 9 7 2004 643
55. B.K. Puri, A.J. Richardson, D.F. Horrobin, T. Easton, N. Saeed, A. Oatridge, J.V. Hajnal, and G.M. Bydder Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes Int. J. Clin. Pract. 54 1 2000 57 63
56. S.K. Raatz, D. Bibus, W. Thomas, and P. Kris-Etherton Total fat intake modifies plasma fatty acid composition in humans J. Nutr. 131 2001 231 234
57. R. Reddy, M. Keshavan, and J.K. Yao Reduced plasma antioxidants in first-episode patients with schizophrenia Schizophr. Res. 62 3 2003 205 212
58. Reddy, R., Keshavan, M., Yao, J.K., in press. Reduced Red Blood Cell Membrane Essential Polyunsaturated Fatty Acids in First-Episode Schizophrenia at Neuroleptic-Naive-Baseline. Schiz. Bull.
59. A.A. Rivellese, and S. Lilli Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes Biomed. Pharmacother. 57 2003 84 87
60. A.A. Rivellese, C. De Natale, and S. Lilli Type of dietary fat and insulin resistance Ann. N. Y. Acad. Sci. 967 2002 329 335
61. P. Sachdev, T. Saharov, and S. Cathart The preventative role of antioxidants (Selegiline and vitamin E) in a rat model of tardive dyskinesia Biol. Psychiatry 46 1999 1672 1681
62. A.P. Simopoulos Omega-3 fatty acids in health and diseases, and in growth and development Am. J. Clin. Nutr. 54 1991 438 463
63. A.P. Simopoulos Human requirement for N-3 polyunsaturated fatty acids Poult. Sci. 79 7 2000 961 970
64. A.P. Simopoulos The importance of the ratio of omega-6/omega-3 essential fatty acids Biomed. Pharmacother. 56 8 2002 365 379
65. C.L. Shiriqui, J. Bradwejn, L. Annable, and B.D. Jones Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study Am. J. Psychiatry 149 3 1992 391 393
66. Soares, K.V., McGrath, J.J., 2000. Vitamin E for Neuroleptic-Induced Tardive Dyskinesia. Cochrane Database Syst Reviews, The Cochrane Collaboration; Issue 2, Oxford: Oxford Update Software, CD000209.
67. L.H. Storlien, A.B. Jenkins, D.J. Chisholm, W.S. Pascoe, S. Khouri, and E.W. Kraegen Influence of dietary fat composition on development of insulin resistance in rat: relationship to muscle triclyceride and omega-3 fatty acids in muscle phospholipid Diabetes 40 1991 280 289
68. M. Strassnig, J.S. Brar, and R. Ganguli Nutritional assessment of patients with schizophrenia: a preliminary study Schizophr. Bull. 29 2 2003 393 397
69. Strassnig, M., Brar, J.S., Ganguli, R., in press. Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr. Res.
70. L.K. Summers, B.A. Fielding, H.A. Bradshaw, V. Ilic, C. Beysen, M.L. Clark, N.R. Moore, and K.N. Frayn Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity Diabetologia 45 3 2002 369 377
71. H.J. Tsay, P. Wang, S.L. Wang, and H.H. Ku Age-associated changes of superoxide dismutase and catalase activities in the rat brain J. Biomed. Sci. 7 2000 466 474
72. B. Vessby, M. Unsitupa, K. Hermansen, G. Riccardi, A.A. Rivellese, L.C. Tapsell, C. Nalsen, L. Berglund, A. Louheranta, B.M. Rasmussen, G.D. Calvert, A. Maffetone, E. Persen, I.B. Gustafsson, and L.H. Storlien Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study Diabetologia 44 2001 312 319
73. P.E. Wainwright Essential fatty acids and behavior: is there a role for the eicosanoids S. Yehuda D. Mostofsky Handbook of Essential Fatty Acid Biology; Biochemistry, Physiology, and Behavioral Neurobiology 1997 Humana Press, Inc. New Jersey 299 341
74. P.E. Wainwright Dietary essential fatty acids and brain function: a developmental prespective on mechanisms Proc. Nutr. Soc. 61 1 2002 61 69
75. World Health Organization Schizophrenia: An International Follow-up Study 1979 Wiley and Sons New York
76. World Health Organization Fats and oils in human nutrition: report of a joint expert consultation. Food and Agriculture Organization of the United Nations and the World Health Organization. FAO Food Nutr. Pap. 57 1995 1 147
77. J.K. Yao, S. Leonard, and R.D. Reddy Membrane phospolipid abnormalities in postmortem brains from schizophrenic patients Schizophr. Res. 42 2000 7 17
78. J.K. Yao, J.A. Stanley, R.D. Reddy, M.S. Keshevan, and J.W. Pettegrew Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites Biol. Psychiatry 52 2002 823 830
79. M. Young, G.C. Hagan, R.E. Tucker, and W.E. Foster A comparison of dietary study methods: 2. Dietary history vs. seven-day record vs. 24-hr recall J. Am. Diet. Assoc. 28 1952 218
80. X.Y. Zhang, D.F. Zhou, L.Y. Cao, C.Q. Xu, C. Chen Da, and G.Y. Wu The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial J. Clin. Psychopharmacol. 24 1 2004 83 86